Seagen Highlights First Solid Tumor Data For An ADCETRIS Immunotherapy Combination And Preclinical Data For Novel CD30-Directed Antibody-Drug Conjugate At Society For Immunotherapy Of Cancer Annual Meeting

Benzinga ·  11/04/2023 00:12

– Initial Phase 2 data presented for ADCETRIS in combination with immunotherapy pembrolizumab in metastatic non-small cell lung cancer and metastatic cutaneous melanoma –– Preclinical data presented for novel antibody-drug conjugate SGN-35T –Seagen Inc. (NASDAQ:SGEN) today announced the first presentation of data evaluating ADCETRIS (brentuximab vedotin) in combination with an anti-PD-1 checkpoint inhibitor in non-small cell lung cancer (NSCLC) and melanoma, and shared preclinical data for an investigational CD30-directed antibody-drug conjugate (ADC) that uses a novel tripeptide linker. The studies were presented at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, taking place November 3-5, 2023, in San

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment